Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL247064 | 1.00 | TP53 (0.35) | TP53SMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL247063 | 1.00 | TP53 (0.35) | TP53SMN1; SMN2NPC1RAB9ATDP1 | |
| SCHEMBL251164 | 0.87 | TP53 (0.39) | TP53SMN1; SMN2CYP3A4TNKS2MDM2 | |
| SCHEMBL251165 | 0.87 | TP53 (0.39) | TP53SMN1; SMN2CYP3A4TNKS2MDM2 | |
| SCHEMBL252374 | 0.84 | TP53 (0.35) | TP53SMN1; SMN2CYP3A4TNKS2PDE3B | |
| SCHEMBL252373 | 0.84 | TP53 (0.35) | TP53SMN1; SMN2CYP3A4TNKS2PDE3B | |
| SCHEMBL15093760 | 0.83 | KDM4E (0.33) | ALDH1A1HPGD | |
| SCHEMBL15093762 | 0.83 | KDM4E (0.33) | ALDH1A1HPGD | |
| SCHEMBL243373 | 0.83 | KDM4E (0.33) | ALDH1A1HPGD | |
| SCHEMBL15153915 | 0.81 | NPC1 (0.36) | TP53NPC1RAB9ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588455-B1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376392-B2 | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296758-B2 | 2-quinolinyl-acetic acid derivatives as HIV antiviral compounds | GILEAD SCIENCES, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. | 2015-02-12 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013103724-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| WO-2013103724-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| EP-2588455-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003498-A1 | 2 -QUINOLINYL- ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045374-A1 | 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS | NFATC1, ACIN1, TERT | TP53 1952/4885SMN1; SMN2 2444/4885NPC1 491/4885 |
| US-20130210801-A1 | 2-QUINOLINYL-ACETIC ACID DERIVATIVES AS HIV ANTIVIRAL COMPOUNDS | NFATC1, ACIN1, ARF1 | TP53 3536/4885SMN1; SMN2 2727/4885NPC1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.